[{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Not Applicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Not Applicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Not Applicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nitazoxanide","moa":"Pyruvate synthase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ Not Applicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Elafibranor","moa":"PPAR gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Not Applicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Elafibranor","moa":"PPAR gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Ipsen"},{"orgOrder":0,"company":"Genfit","sponsor":"Genoscience Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Genfit \/ Genoscience Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Genfit \/ Genoscience Pharma"},{"orgOrder":0,"company":"Genfit","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ezurpimtrostat","moa":"PPT1","graph1":"Oncology","graph2":"Phase I","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genfit \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genfit \/ Not Applicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Versantis","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Genfit","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Genfit \/ Genfit","highestDevelopmentStatusID":"6","companyTruncated":"Genfit \/ Genfit"},{"orgOrder":0,"company":"Genfit","sponsor":"Seal Rock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"SRT-015","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Genfit","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0.11,"dosageForm":"Suspension","sponsorNew":"Genfit \/ Genfit","highestDevelopmentStatusID":"6","companyTruncated":"Genfit \/ Genfit"},{"orgOrder":0,"company":"Genfit","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Elafibranor","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Genfit \/ Genfit","highestDevelopmentStatusID":"10","companyTruncated":"Genfit \/ Genfit"},{"orgOrder":0,"company":"Genfit","sponsor":"Celloram","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CLM-022","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Genfit","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Genfit \/ Genfit","highestDevelopmentStatusID":"4","companyTruncated":"Genfit \/ Genfit"},{"orgOrder":0,"company":"Genfit","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"VS-01","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0.19,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.19,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Genfit \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ HealthCare Royalty"},{"orgOrder":0,"company":"Genfit","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"VS-01","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0.20000000000000001,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Genfit \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ HealthCare Royalty"}]

Find Clinical Drug Pipeline Developments & Deals by Genfit

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The financing aims to advance the company's product pipeline including VS-01, an investigational drug based on a proprietary scavenging liposomal technology. It is treated in patients with ACLF.

Product Name : VS-01

Product Type : Other Small Molecule

Upfront Cash : $141.2 million

March 20, 2025

Lead Product(s) : VS-01

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Phase II

Sponsor : HealthCare Royalty

Deal Size : $201.7 million

Deal Type : Financing

blank

02

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The company will use the proceeds to develop its pipeline focused on Acute-on-Chronic Liver Failure (ACLF), including VS-01, a first-in-class innovative liposomal-based therapeutic product.

Product Name : VS-01

Product Type : Other Small Molecule

Upfront Cash : $133.2 million

January 30, 2025

Lead Product(s) : VS-01

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Phase II

Sponsor : HealthCare Royalty

Deal Size : $189.5 million

Deal Type : Financing

blank

03

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Under the agreement, GENFIT will advance Celloram’s first-in-class inflammasome inhibitor, CLM-022, a triterpenoid derivative that targets the inflammasome machinery, in liver disease indications.

Product Name : CLM-022

Product Type : Small molecule

Upfront Cash : Undisclosed

July 31, 2023

Lead Product(s) : CLM-022

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Preclinical

Recipient : Celloram

Deal Size : $175.5 million

Deal Type : Licensing Agreement

blank

04

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : GFT505 (elafibranor) is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease.

Product Name : GFT505

Product Type : Small molecule

Upfront Cash : Not Applicable

June 30, 2023

Lead Product(s) : Elafibranor

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Phase III

Recipient : Ipsen

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Under the agreement, GENFIT has gained the exclusive worldwide rights of SRT-015, a highly optimized, first-in-class ASK1 inhibitor being developed in acute-on-chronic liver failure (ACLF), from Seal Rock Therapeutics.

Product Name : SRT-015

Product Type : Small molecule

Upfront Cash : Undisclosed

May 31, 2023

Lead Product(s) : SRT-015

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Phase I

Recipient : Seal Rock Therapeutics

Deal Size : $106.8 million

Deal Type : Licensing Agreement

blank

06

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : VS-01, is a first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development as a potential first-line therapy for the timely recovery of ACLF and UCD.

Product Name : VS-01

Product Type : Small molecule

Upfront Cash : Undisclosed

September 19, 2022

Lead Product(s) : VS-01

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Phase I

Recipient : Versantis

Deal Size : $107.6 million

Deal Type : Acquisition

blank

07

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : GNS561 (ezurpimtrostat) is a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor that blocks autophagy. Autophagy is activated in tumor cells in response to certain conditions, due to a tumor cell growth in advanced cancers.

Product Name : GNS561

Product Type : Small molecule

Upfront Cash : Not Applicable

September 13, 2022

Lead Product(s) : Ezurpimtrostat

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : The agreement gives Ipsen exclusive worldwide* license to develop, manufacture and commercialize GENFIT’s GFT505, an investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC).

Product Name : GFT505

Product Type : Small molecule

Upfront Cash : $137.7 million

December 17, 2021

Lead Product(s) : Elafibranor

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Phase III

Sponsor : Ipsen

Deal Size : $583.0 million

Deal Type : Licensing Agreement

blank

09

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Through the acquisition of exclusive rights from Genoscience Pharma to develop and commercialize the investigational treatment GNS561 in cholangiocarcinoma in the United States, Canada and Europe, including the United Kingdom and Switzerland.

Product Name : GNS561

Product Type : Small molecule

Upfront Cash : Undisclosed

December 17, 2021

Lead Product(s) : Ezurpimtrostat

Therapeutic Area : Oncology

Highest Development Status : Phase I/ Phase II

Sponsor : Genoscience Pharma

Deal Size : $3.4 million

Deal Type : Acquisition

blank

10

ELCC
Not Confirmed
ELCC
Not Confirmed

Details : Company presents Elafibranor, dual agonism of peroxisome proliferator-activated alpha/delta receptors found to be efficacious in the treatment of PBC, a rare liver disease.

Product Name : GFT505

Product Type : Small molecule

Upfront Cash : Not Applicable

November 02, 2021

Lead Product(s) : Elafibranor

Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status : Phase III

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank